Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: markets are closed for President's Day holiday

February 17, 2020 1:39pm

Friday's title: Bottom fishers are weighting diminished equities while sector slips

The week in review

Pre-open indications: 4 HITs <Brain Cell Therapeutics (BCLI +$0.24), BioLife Solutions (BLFS +$0.35), Regenxbio (RGNX -$0.40), ReNeuron (RENE.L -$2.50)> and 2 MISS <Ultragenyx Pharmaceutical Inc. (RARE -$1.77), Editas Medicine (EDIT -$0.02)>

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks

The Dow closed DOWN -25.23 points (-0.09%), the S&P closed UP +6.22 points (+0.18%) and the NASDAQ closed UP +19.21 points (+0.20%)

Henry’omics:

Indexes were little changed on Friday, but notched a gain for the week; also, with a couple of sector earnings (RARE with a wider than expected Q4 loss as CRSP followed ALNY) and all were down in Friday’s sector exchange.

For the week, the S&P 500 rose +1.6% and the Dow 1% with the Nasdaq gaining 2.2%.

Flirting with a disaster, it’s the second day in a row that China has revised infection and death data changes fueling doubts many have about their accuracy.

From my a.m.’s Data Docket: core retail sales, which exclude autos, gas, building materials and food services, were unchanged last month; bottom line – consumers are spend less.

Today’s session: Pluristem (PSTI +$0.77) with 1.03 M shares traded as compared to the 3-month average of 128.7 K shares traded and Precigen (PGEN +$0.40) with 1.824 M shares traded as compared to the 3 month average of 1.81 M shares traded are the winningest equities of the session, how long will they last (?)

While, the gene editors get whacked (NTLA -$1.65, CRSP -$2.32 and EDIT -$0.02) as Sangamo Therapeutics (SGMO) closed flat at $7.57.

Adverum Biotechnologies (ADVM closed its offering of 10,925,000 shares priced at $13.75 per share, which included the full exercise of the underwriters’ option to purchase up to an additional 1,425,000 shares of common stock. The gross proceeds to Adverum before deducting underwriting discounts and commissions and offering expenses payable by Adverum were approximately $150.2 M.

Ask yourself, do you know why you own a certain equity?

What’s been communicated re a company’s status at any given time to shareholders - are you reading 8-Ks, waiting for the next quarterly reports or a once-upon-a-time press un-release!

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Friday the IBB closed up +0.43% and XBI closed up +0.18%
Thursday the IBB closed down -0.99% and XBI closed down -1.09%
Wednesday the IBB closed up +0.27% and XBI closed up +1.25%
Tuesday the IBB closed down -0.06% and XBI closed down -0.11%
Monday the IBB closed up +1.20% and XBI closed up +1.55%

The advance/decline line scenario of 35 covered companies:

Friday the close was negative with an A/D line of 14/19, 2 flats of 35 covered;
Thursday the close was negative with an A/D line of 13/20, 2 flats of 35 covered;
Wednesday the close was positive with an A/D line of 26/8, 1 flat of 35 covered;
Tuesday the close was positive with an A/D line of 22/12, 1 flat of 35 covered;
Monday the close was positive with an A/D line of 26/6, 3 flats of 35 covered;

Decliners:

ReNeuron (RENE.L -$2.50);
CRISPR Therapeutics (CRSP -$2.32 after Thursday’s +$0.37);
Ultragenyx (RARE -$2.32);
Intellia Therapeutics (NTLA -$1.65);
Alnylam Pharmaceuticals (ALNY -$1.40 after Thursday’s -$3.89, Wednesday’s +$4.45, Tuesday’s -$1.96 and Monday’s +$6.02);
Global Blood Therapeutics (GBT -$0.98 after Thursday’s-$3.26, Wednesday’s +$1.53, Tuesday’s +$0.91 and Monday’s +$1.98);

Incliners:

Pluristem (PSTI +$0.77)
Fate Therapeutics (FATE +$0.76);
AxoGen (AXGN +$0.56);
Adverum Biotechnologies (ADVM +$0.52)
Precigen (PGEN +$0.40) – spin-out of Intrexon (XON);
Bellicum Pharmaceuticals (BLCM +$0.40) after reverse split;

The percentage (%) indicators:

Friday’s range of the 14-upside was +0.06% (CLLS) to +19.79% (PSTI) while the 19-downside ranged from -0.05% (QURE) to -10.64% (NTLA);
Thursday’s range of the 13-upside was +0.03% (RARE) to +14.41% (BCLI) while the 20-downside ranged from -0.07% (EDIT) to -5.84% (PGEN);
Wednesday’s range of the 26-upside was +0.33% (IONS) to +5.34% (ADRO) while the 8-downside ranged from -0.48% (EDIT) to -5.77% (BSTG);
Tuesday’s range of the 22-upside was +0.15% (STML) to +19.13% (ADVM) while the 12-downside ranged from -0.66% (BLUE) to -10.48% (BLCM after a reverse split);
Monday’s range of the 26-upside was +0.25% (BCLI) to +17.68% (ADVM) while the 6-downside ranged from -0.74% (ATHX) to -4.74% (PSTI);

Upside volume stats: to compare

Friday: 7 out of the 14-upside had higher than the 3-month average volume;
Thursday: 5 out of the 13-upside had higher than the 3-month average volume;
Wednesday: 5 out of the 26-upside had higher than the 3-month average volume;
Tuesday: 6 out of the 22-upside had higher than the 3-month average volume;
Monday: 6 out of the 26-upside had higher than the 3-month average volume;

Downside volume stats:

Friday: 3 out of the 19-downside had higher than the 3-month average volume;
Thursday: 0 out of the 20-downside had higher than the 3-month average volume;
Wednesday: 0 out of the 8-downside had higher than the 3-month average volume;
Tuesday: 1 out of the 12-downside had higher than the 3-month average volume;
Monday: 1 out of the 6-downside had higher than the 3-month average volume;

2 flat – BSTG and SGMO

February

Friday closed negative with 19 decliners, 14 advancers and 2 flats

Thursday closed negative with 20 decliners, 13 advancers and 2 flats

Wednesday closed positive with 8 decliners, 26 advancers and 1 flat

Tuesday closed positive with 12 decliners, 22 advancers and 1 flat

Monday closed positive with 6 decliners, 26 advancers and 3 flats

Friday closed negative with 26 decliners, 9 advancers and 0 flat

Thursday closed negative with 23 decliners, 12 advancers and 0 flat

Wednesday closed positive with 5 decliners, 27 advancers and 3 flats

Tuesday closed positive with 5 decliners, 30 advancers and 0 flats

Monday (2/3) closed positive with 8 decliners, 24 advancers and 3 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 57 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.